

## Denmark

<b>Population (January 2013):</b>	5 602 628
<b>Human development Index (2013):</b>	0.899
<b>HAV vaccine recommendations:</b>	HAV vaccination is not included in the national childhood immunisation programme. Vaccination is recommended for: 1. travellers to endemic areas (not publically reimbursed). Contacts to cases of hepatitis A are offered free vaccination (postexposure). Vaccination is recommended to risk groups for hepatitis B in the form of the combined hep A/B vaccine.
<b>Seroprevalence studies by quality score:</b>	score 0: 1 study score 1: 2 studies score 2: 1 study
<b>Seroprevalence studies timeframe:</b>	1976–2003

Seroprevalence assessment: **very low**  
Incidence assessment: **low**  
Susceptibility in adults: **very high**

Two studies conducted before 1990 estimated HAV seroprevalence in the under 30 years of age to be below 50%. No study estimated HAV seroprevalence in this age group between 1990 and 2000, but among 35–49 years old it was 15.9% according to one 1991 study. In 2003, HAV seroprevalence was 25% or less in all age groups. Therefore, Denmark is a very low endemicity country (Denmark\_Figure 1) and has likely been since at least the mid-1970s.

**Denmark\_Table 1. Hepatitis A seroprevalence level by time period**


	Very low endemicity	Low endemicity	Intermediate endemicity
1975–1989			
1990–1999			
2000–2013			

Reported incidence was already below 20/100 000 in the early 1980s, and has been decreasing since (Denmark\_Figure 2). TESSy data is consistent with a very low endemicity picture; apart from an incidence slightly over 5 in 2007, reported incidence has been under 2/100 000 every year since at least 2006.


Susceptibility levels by 30 years are around 95% and by 60 years at least 75% are susceptible. Therefore, the susceptibility among adults is very high.

Denmark\_Figure 1 (panel a). Summary of seroprevalence in Denmark, by age and time period


Panel a.1: 1975–1989




Panel a.2: 1990–1999




Panel a.3: 2000–2013



**Denmark\_Figure 1 (panel b). Summary of seroprevalence in Denmark, by age and time period (1975–2013**



**Denmark\_Figure 2. Reported incidence of hepatitis A, Denmark, 1980–2013**

## Bibliography

1. Christensen PB, Homburg KM, Sorensen LT, Georgsen J. Hepatitis A infection and vaccination among Danish blood donors. *Scand J Infect Dis.* 2005;37(2):127-30.
2. Linneberg A, Ostergaard C, Tvede M, Andersen LP, Nielsen NH, Madsen F, et al. IgG antibodies against microorganisms and atopic disease in Danish adults: the Copenhagen Allergy Study. *J Allergy Clin Immunol.* 2003 Apr;111(4):847-53.
3. Mathiesen LR, Skinhoj P, Hardt F, Nielsen JO, Sloth K, Zoffmann H, et al. Epidemiology and clinical characteristics of acute hepatitis types A, B, and non-A non-B. *Scand J Gastroenterol.* 1979;14(7):849-56.
4. Skinhoj P. Epidemiological aspects of viral hepatitis A and B infections. A review with special reference to serological studies in isolated areas. *Dan Med Bull.* 1981;28(5):177-92.
5. Tornberg E, Ronne T. [Occurrence of hepatitis A infection in Denmark]. *Ugeskr Laeger.* 1997 May 5;159(19):2856-61.
6. Wandall DA, Christiansen AH, Samuelsson IS. [Hepatitis A in Denmark. Notified cases 1996-1999]. *Ugeskr Laeger.* 2000 Nov 13;162(46):6233-6.